What is corneal collagen cross-linking?
Corneal collagen cross-linking (CXL) is a new, noninvasive treatment for keratoconus. CXL involves applying a photosensitizing solution consisting of Riboflavin (vitamin B2) to the cornea and exposing it to a low dose of ultraviolet light. The photosensitizer reacts with the ultraviolet light to create new collagen bonds (cross-links) throughout the cornea. In corneas affected by keratoconus there are too few collagen bonds to maintain structural integrity. The reduced number of collagen bonds and weakened configuration result in corneal bulging, steepening, and irregularity all of which significantly affect vision. By creating new collagen bonds, CXL strengthens and adds resilience to corneas weakened by keratoconus. If performed early enough, CXL can counteract its effects and allow good vision to preserved. In advanced cases, CXL can postpone the need for invasive corneal transplants and prevent vision from getting worse.
